Evidence map›Paper›PMID 40006991›Full record

ArticleViruses2025

Prevalence and Risk Factors of Occult HCV Infection in the Adult Population of Mexico City.

Luis Antonio Uribe-Noguez, María Erandhi Prieto-Torres, Luis Octavio Uribe-Noguez, José Antonio Mata-Marín, Carla Ileana Arroyo-Anduiza, Rebeca Paquentín-Jimenez, Alberto Chaparro-Sanchez, Wendy Guadalupe Vazquez-Gonzalez, Andrea Santos Coy-Arechavaleta, Ericka Nelly Pompa-Mera and 4 more

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. [Screening of Hepatitis C virus in blood donors over 11 years].Revista medica del Instituto Mexicano del Seguro Social · 2026
    Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Luis Antonio Uribe-NoguezLaboratorio Central de Epidemiología, División de Laboratorios Especializados, Centro Médico Nacional (CMN) "La Raza", IMSS, México City 02990, Mexico.ORCID 0000-0003-2452-782X
María Erandhi Prieto-TorresCoordinación de Información y Análisis Estratégico, Instituto Mexicano del Seguro Social (IMSS), Mexico City 77503, Mexico.
Luis Octavio Uribe-NoguezSalud Digna, Mexico City 55717, Mexico.
José Antonio Mata-MarínDepartamento de Enfermedades Infecciosas, Hospital de Infectología, CMN "La Raza", IMSS, Mexico City 02990, Mexico.ORCID 0000-0002-3701-9894
Carla Ileana Arroyo-AnduizaDepartamento de Patología Clínica, Banco Central de Sangre, CMN "La Raza", IMSS, México City 02990, Mexico.
Rebeca Paquentín-JimenezInflammatory Eye Disease Clinic, Asociación Para Evitar la Ceguera en México, Hospital "Dr. Luis Sánchez Bulnes", México City 04030, Mexico.ORCID 0000-0001-7053-3601
Alberto Chaparro-SanchezDepartamento de Enfermedades Infecciosas, Hospital de Infectología, CMN "La Raza", IMSS, Mexico City 02990, Mexico.ORCID 0000-0001-8480-0408
Wendy Guadalupe Vazquez-GonzalezLaboratorio Central de Epidemiología, División de Laboratorios Especializados, Centro Médico Nacional (CMN) "La Raza", IMSS, México City 02990, Mexico.ORCID 0000-0002-7318-4897
Andrea Santos Coy-ArechavaletaLaboratorio Central de Epidemiología, División de Laboratorios Especializados, Centro Médico Nacional (CMN) "La Raza", IMSS, México City 02990, Mexico.
Ericka Nelly Pompa-MeraUnidad de Investigación en Enfermedades Infecciosas y Parasitarias, Hospital de Pediatría, CMN "Siglo XXI", IMSS, Mexico City 06720, Mexico.ORCID 0000-0002-8458-3703
Jesus Gaytán-MartínezDepartamento de Enfermedades Infecciosas, Hospital de Infectología, CMN "La Raza", IMSS, Mexico City 02990, Mexico.
Julio Elias Alvarado-YaahLaboratorio Central de Epidemiología, División de Laboratorios Especializados, Centro Médico Nacional (CMN) "La Raza", IMSS, México City 02990, Mexico.
Clara Esperanza Santacruz-TinocoDivisión de Laboratorios Especializados, Instituto Mexicano del Seguro Social, Mexico City 07760, Mexico.
Alicia Ocaña-MondragónLaboratorio Central de Epidemiología, División de Laboratorios Especializados, Centro Médico Nacional (CMN) "La Raza", IMSS, México City 02990, Mexico.

Funding

Consejo Nacional de Ciencia y Tecnología SALUD-2015-1-261113Fondo en Investigación en Salud FIS/IMSS/PROT/G15/1411
6 · The paper itself

Abstract

Occult HCV infection (OCI) is defined by the presence of HCV RNA in hepatocytes and/or peripheral blood mononuclear cells (PBMCs) without detectable HCV RNA or anti-HCV antibodies in plasma. OCI is underrecognized and may contribute to HCV transmission. This study estimated OCI prevalence and associated risk factors in adults from Mexico City.

Indexed as

HepacivirusHepatitis CAdolescentAdultAgedCross-Sectional StudiesFemaleGenotypeHepatitis C AntibodiesHumansLeukocytes, MononuclearMaleMexicoMiddle AgedPhylogenyPrevalenceHepatitis C AntibodiesRNA, Viralgeneral populationHCVoccult HCV infectionrisk factorssequencing

Identifiers

PMID40006991
PMCPMC11860181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.